Business Wire

CA-AKTANA,-INC.

5.3.2024 13:01:34 CET | Business Wire | Press release

Share
Aktana Announces Release of Next Generation Omnichannel Orchestration Tools Designed for Medical Technology Companies

Aktana, Inc., the leader in intelligent customer engagement for global life sciences and the medical industry, today announced the availability of “Aktana for MedTech,” a set of tools designed to optimize field representative execution, account coordination and medical education programs with AI-powered insights and guidance.

The solution includes Aktana Copilot Mobile for MedTech, an interactive digital assistant that optimizes the execution of sales and marketing strategies across field commercial teams via mobile devices, delivering true omnichannel performance and impact.

“HCPs have overwhelmingly expressed their desire to leverage multiple digital channels to conduct their own research, interact with colleagues and engage with medical company representatives," said John Vitalie, CEO of Aktana. “However, less than 20% of MedTech companies are using advanced omnichannel capabilities. Those doing so are outpacing the industry in revenue by 2x.”

“Aktana for MedTech takes omnichannel to a completely new level by allowing medical device companies to plan and manage their interactions with HCPs through AI-guided intelligence all the way from pre-launch through to face-to-face meetings in the field to follow-up. At the same time, Aktana Copilot Mobile for MedTech captures real-time field reaction data, improving intelligence in real-time with every HCP interaction,” Vitalie continued.

Aktana for MedTech is comprised of Aktana’s world-class open platform, Field Orchestrator, Omnichannel Orchestrator, Analytics Activator, as well as Copilot Mobile. The tools use real-time, intelligence-driven nudges to field teams to simplify call planning and drive more personalized and coordinated activities, ultimately enhancing the quality of interactions with HCPs. Specifically, Aktana for MedTech:

  • Allows medical technology companies to simplify scheduling, manage stock, optimize inventory utilization and streamline procurement processes with AI-powered omnichannel orchestration.
  • Predicts product thresholds with AI-driven identification of critical account-level product volume changes, combined with dynamic actionable suggestions, to increase sales and decrease costs.
  • Delivers medical education content far more effectively with dynamic actionable suggestions to ensure HCPs are getting the best information at the right time to better serve patients.

Concurring with research regarding physician preferences, Dr. Adil Ajuied, a knee surgeon at Guy's and St Thomas' NHS Foundation Trust and the Fortius Clinic London, says, "Being able to streamline the appointment scheduling process by analyzing my availability, preferences, and historical engagement patterns could ensure that meetings are scheduled at optimal times, minimizing disruptions to my clinical responsibilities, and allowing for more focused discussions."

Aktana for MedTech is CRM-agnostic and can integrate with all data sources. The set of tools is modular and can be deployed individually or combined with any of Aktana’s products. Aktana for MedTech is available immediately.

Connect with Aktana on LinkedIn: www.linkedin.com/company/aktana

Follow @aktana_inc on Twitter: www.twitter.com/aktana_inc

About Aktana

Aktana is the leader in intelligent customer engagement for global life sciences and the medical industry. By ensuring that every customer experience is tailored to individual preferences and needs, we help life science companies strengthen their relationships with healthcare providers to inspire better patient care. Aktana transforms the commercial engagement model to make each interaction more effective with proprietary blended-AI and mobile intelligence. Today, commercial and medical teams from more than 350 brands use Aktana’s next generation-AI complete orchestration to deliver personalized omnichannel engagement at scale. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305334832/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes16.9.2026 09:00:00 CEST | Press release

Aqara, a global leader and pioneer in IoT, today announced the release of the Spatial Multi-Sensor FP400. The FP400 is designed to bring precise, spatial intelligence to homes without sacrificing the privacy typically compromised by smart cameras. Rather than simply detecting motion or presence, the FP400 enables homes to better understand occupancy, movement, and context for more granular and personalized automations and insight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916958372/en/ Aqara Announces the Availability of The Spatial Multi-Sensor FP400, Offering Advanced Spatial Intelligence for Smart Homes The Spatial Multi-Sensor FP400 redefines how smart homes perceive and interact with living spaces by combining high-precision spatial sensing with AI-powered environmental understanding. Powered by a next-generation high-precision 60GHz mmWave radar, the FP400 delivers industry-leading multi-person sensing, precise

Cambridge Associates Opens Italian Office and Expands European Leadership16.9.2026 09:00:00 CEST | Press release

Global investment firm Cambridge Associates (CA) today announced the opening of a new office in Milan and the appointment of two senior hires in Europe. The move reflects the firm’s ongoing commitment to providing bespoke services to current and future institutional and family office investors across the region. Raphael Heynold has joined the Client Solutions team as Head of EMEA and APAC and will serve on the firm’s EMEA Operating Committee. Based in London, Raphael is a key member of the Global Client Solutions Leadership team, responsible for driving growth and market expansion and overseeing client engagement efforts across Europe, the Middle East, and Asia Pacific regions. Heynold brings more than 30 years of experience across client strategy, investment banking and investment management, and has worked with many sophisticated families and institutions around the world. Riccardo Pianeti has joined Cambridge Associates to lead the Italian office. He will serve as Head of the Milan

International Expansion Far Outweighs M&A as a Legal and Compliance Execution Burden, CSC Research Finds16.9.2026 08:49:00 CEST | Press release

International expansion far outweighs M&A as a legal and compliance execution burden, cited by 74% of senior cross-border professionals versus 28%54% often redo work because entity or ownership information is incomplete or outdatedHalf say information gaps can add one to two weeks to cross-border work International expansion is creating a far heavier legal and compliance execution burden than M&A itself, with nearly three quarters (74%) of senior cross-border professionals citing market entry or international expansion as a leading burden, compared with just 28% for M&A transactions, according to new research from CSC, the leading provider of global business administration and compliance solutions. The challenge extends well beyond deal execution. Ongoing entity governance and compliance is cited by 71% of respondents, highlighting the operational burden of establishing and maintaining a presence across multiple jurisdictions. CSC’s new report, The Cross-Border Readiness Gap: Navigatin

Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer16.9.2026 08:00:00 CEST | Press release

An expert in scaling medical innovations, Marion Ghibaudo joins Okomera as the company advances toward industrial deployment. Okomera, a TechBio company pioneering next-generation cancer care through the development of a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the appointment of Marion Ghibaudo as Chief Technology Officer. She will spearhead the company’s technology and innovation strategy and lead the industrial deployment of its integrated hardware, software, and biological platform. Marion Ghibaudo will join Okomera’s Executive Committee and report to CEO Silvère Lucquin. In parallel, Raphaël Tomasi, Okomera’s co-founder and former CTO, transitions to the role of VP Platform, ensuring continuity in the development of the company’s technology platform. Marion’s appointment comes at a key stage in Okomera’s growth as the company advances toward pilot studies, industrial scale-up, and commercialization. Okomer

Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 07:00:00 CEST | Press release

Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1 These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3 Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye